NATIONAL PHILANTHROPIC TRUST ANNOUNCES TOM BRILLI AS CHIEF PRODUCT OFFICER
Brilli to inaugurate new leadership role at the largest, independent donor-advised fund public charity
"As part of our continued commitment to innovation and focus on customer experience, NPT has established a dedicated CPO role on our Executive Team—an essential step in shaping our future and delivering impactful solutions to those we serve," said
Brilli joins NPT after serving as the Executive Director, Head of Donor-Advised Funds for J.P. Morgan. This pivotal role included leading the donor-advised fund program across three lines of business. Additionally, he was responsible for the regulatory implementation of the Dodd Frank rules and served as the head of Product Development for the bank's institutional clients in the US and Latin American regions.
"When NPT announced this new position, I knew it was the chance of a lifetime to help evolve the impact of donor advised funds and philanthropy overall for the benefit of donors and grantees alike," said Brilli.
Before joining J.P. Morgan, Brilli held leadership positions at Sapient Global Markets, Jefferies, and Deutsche Bank. His academic background includes a Bachelor of Science degree from Fairfield University and a Master of Business Administration from PACE University. Brilli resides in central
About National Philanthropic Trust
Founded in 1996, National Philanthropic Trust (NPT) is the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/national-philanthropic-trust-announces-tom-brilli-as-chief-product-officer-302544120.html
SOURCE National Philanthropic Trust
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Copenhagen Infrastructure Partners invests in Via Verde, Italian biomethane platform
- Bundesliga resolves 89 percent of fan questions at first contact with ServiceNow CRM
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Deutsche Bank, JPMorgan, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share